Hello, Welcome to Shine Consultant !
Summit & Event Shine Speaker Bureau Shine Advisor Shine Event Service
  • Summit & Event :
    With field research of markets and industries which is analyzed from a global strategic perspective by our professional teams, as well as hot topics which interest leadership and management, Shine Consultant provides you with one-stop platform of dialogue, practice -sharing and social network!
  • Shine Speaker Bureau:
    Committed to provide keynote speakers, executive learning masterclasses and boardroom advisory for global enterprises and institutions, each service provides a deeper and more interactive experience, especially for small, selected audiences and key individuals. We have the resources of the most influential business leaders and experts, who are the most outstanding representatives in their fields. Our team consists of experienced speech and event managers, and we focus on building long-term and in-depth partnerships.
  • Shine Advisor:
    As world-class insight network, we connects clients-decision makers with vetted subject matter experts-advisors. Our clients leverage the insights and perspectives shared by our advisors to stay informed and make better business decisions.We have over 600,000 Shine Advisors in 20 industries, which continues to grow every day.
  • Shine Event Service:
    Committed to be the world's most professional provider of industrial Summit & Event. We provide one-stop professional services, including investigating and planning, on-demand inviting, marketing and promoting, operating, project management, live& digital conference, each service is performed by an experienced professional team matched with long-term industrial resources. We focus on establishing long-term and in-depth partnerships.
Guest Information
发布时间: 2018 - 11 - 14
点击次数: 0
Positions: SVP,Regulatory Affairs and Drug Development Strat
Company: Beijing Shenogen Pharma Group Ltd.
个人简介:
Dr. Jian Peng is Senior Vice President of ShenogenPharma Group, responsible for regulatory affairs and drug development strategy. Dr. Peng has high reputation in drug regulatory and drug development, and has worked in the field for the last 20 years. Prior to joining Shenogen, he served as scientific advisor, director of clinical research & oncology head of Asia Pacific, Sanofi, sequentially. Before that, Dr. Peng was in charge of oncology drug approval in Center of Drug Evaluation (CDE), Chinese Food and Drug Administration (CFDA). He was lead director of the program for oncology drug clinical research and evaluation, which helped to improve quality of clinical trials in China. Dr. Peng played a key role in leading several Chinese first-in-class oncology drugs to approval, including Icotinib from BettaPharma, Apatinib from Heng Rui Medicine, Chidamide from Chipscreen. He was also the leader of Oxaliplatin (Sanofi) clinical trials and regulatory process in China. Dr. Peng got his PhD degree from China Pharmaceutical University and master degree from China Academy of Chinese Medicine Sciences. Dr. Peng is author/co-author of more than 20 SCI papers and serves as a member of Chinese Society of Clinical Oncology (CSCO).
发布时间: 2018 - 11 - 14
点击次数: 0
Positions: Senior Vice President Great China
Company: Fountain Medical Development LTD
个人简介:
Dr. Gongshu Li is Senior Vice President Great China of Fountain Medical Development LTD. Responsible for the registration and medical affairs,Chief Medical Officer of Chinese and Botanica Medicine.She served as the senior reviewer and deputy office director of the office of TCM clinical evaluation in the Center for DrugEvaluation( CDE) of the ChinaFood and Drug Administration( CFDA) for 12 years.She was the director of the institutions office of Guang 'anmen hospital of the China Academy of Chinese Medicine Sciences for 3 years. She graduated from China Academy of Chinese Medicine Sciences.Doctor of medicine in oncology. She worked as anoncologist for ten years.
发布时间: 2018 - 11 - 20
点击次数: 0
Positions: Founder and CEO
Company: Adagene Inc.
个人简介:
Dr. Peter (Peizhi) Luo, the founder and Chief Executive Officer of Adagene, is an experienced entrepreneur passionate on devising a sustainable biotechnology business strategy by leveraging the industry’s most advanced technology and intellectual property for novel product development. He utilizes a multi-disciplinary approach to his work, combining methods from experimental and computational biology, chemistry, and physics.Prior to this, Dr. Luo was the Chief Technology Officer of Abmaxis Inc., a wholly owned subsidiary of Merck & Co., and Director of Biologics Technology at Merck & Co., Inc. Before the acquisition of Abmaxis by Merck in 2006, Dr. Luo was the Cofounder, Chief Technology Officer, President and a Board Director of Abmaxis Inc. During Dr. Luo’s time at Merck, he designed and built the antibody libraries and engineering platforms that propelled the discovery of Merck’s novel biologics. He received two Merck Special Achievement Awards for his leadership and scientific contribution. Before his work at Abmaxis, Dr. Luo served as the first lead scientist in computational protein design and protein laboratory at Xencor. Through his work at Stanford, Dr. Luo discovered the fundamental mechanisms of protein folding and stability concerning the solvation of peptide backbone by cosolvents and amino acid side-chains.Dr. Luo completed his postdoctoral research in protein folding with Dr. Robert L. Baldwin at Stanford University. He received his Ph.D. in chemistry under the guidance of Dr. David G. Lynn at The University of Chicago, M.S. degree in applied physics from The Institute of High Energy Physics of the Chinese Academy of Sciences, and B.S. degree in applied chemistry from Peking University.
发布时间: 2018 - 11 - 20
点击次数: 0
Positions: Founder & CEO
Company: Abbisko Therapeutics Co., Ltd.
个人简介:
Abbisko Therapeutics Co., Ltd.